MEDIFAST INC(MED)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,799 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in MED
Events flagged as statistical outliers against MED's own multi-year baseline — not fixed dollar thresholds.
- Record insider buy2026-08-26
Largest insider buy on record for MED: Kiai Parsa (Director) purchased $514,748
View source filing → - Record insider buy2026-08-20
Largest insider buy on record for MED: Kiai Parsa (Director) purchased $487,065
View source filing →
MED Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for MEDIFAST INC (MED), a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores MED at 19.1/100 on a 32-signal composite quality model, placing it at rank #2,799 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.9) and institutional flow (5.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 40.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MEDIFAST INC reports quarterly revenue of $76.4M, net income of $-3.1M, an operating margin of -5.7%. Top institutional holders of MED by reported 13-F value include RENAISSANCE TECHNOLOGIES, Steamboat Capital Partners, SUSQUEHANNA INTERNATIONAL GROUP, LLP, based on the most recent SEC filings. MED trades on the NYSE exchange and files with the SEC under CIK 910329. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MED daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MEDIFAST INC directly from SEC EDGAR. MEDIFAST INC's 13F Pro composite quality score has ranged between 19 and 74 since 2021, currently 19.1 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$76.4M
Net Income
Q2 2026
$-3.1M
Free Cash Flow
Q2 2026
$728.0K
Operating Margin
Q2 2026
-5.7%
ROIC
Q2 2026
-8.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-36.0% YoYNet Income
-993.0% YoYOperating Income
-593.8% YoYEPS (Diluted)
-994.7% YoYTotal Assets
-12.8% YoYOp. Cash Flow
-72.0% YoYFree Cash Flow
-92.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $385.8M -36.0% | $602.5M -43.8% | $1.07B -32.9% | $1.60B +4.8% | $1.53B +63.2% | $934.8M |
| Net Income | $-18.7M -993.0% | $2.1M -97.9% | $99.4M -30.8% | $143.6M -12.5% | $164.0M +59.5% | $102.9M |
| Operating Income | $-14.2M -593.8% | $2.9M -97.7% | $126.4M -31.6% | $184.8M -14.5% | $216.2M +61.2% | $134.2M |
| EPS (Diluted) | $-1.70 -994.7% | $0.19 -97.9% | $9.10 -28.5% | $12.73 -8.4% | $13.89 +60.0% | $8.68 |
| Total Assets | $248.0M -12.8% | $284.2M -8.3% | $309.9M -2.0% | $316.2M -20.6% | $398.3M +44.3% | $276.1M |
| Operating Cash Flow | $6.9M -72.0% | $24.5M -83.4% | $147.7M -24.1% | $194.6M +105.8% | $94.5M -34.9% | $145.2M |
| Free Cash Flow | $1.2M -92.7% | $17.0M -87.9% | $141.2M -20.6% | $177.9M +194.8% | $60.3M -56.7% | $139.3M |
Get alerted when MED's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MEDIFAST INC including:
Top Institutional Holders of MED
RENAISSANCE TECHNOLOGIES LLC
$8.3M778,610 shSteamboat Capital Partners, LLC
$7.5M706,699 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$5.8M542,700 shTWO SIGMA INVESTMENTS, LP
$5.1M481,381 shVANGUARD CAPITAL MANAGEMENT LLC
$4.7M446,614 shCHARLES SCHWAB INVESTMENT MANAGEMENT INC
$4.2M396,996 shBlackRock, Inc.
$3.9M369,503 shDIMENSIONAL FUND ADVISORS LP
$3.9M363,394 shAMERICAN CENTURY COMPANIES INC
$3.4M318,911 shMORGAN STANLEY
$3.1M292,508 sh
| Fund | Value | Shares |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $8.3M | 778,610 |
| Steamboat Capital Partners, LLC | $7.5M | 706,699 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5.8M | 542,700 |
| TWO SIGMA INVESTMENTS, LP | $5.1M | 481,381 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.7M | 446,614 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4.2M | 396,996 |
| BlackRock, Inc. | $3.9M | 369,503 |
| DIMENSIONAL FUND ADVISORS LP | $3.9M | 363,394 |
| AMERICAN CENTURY COMPANIES INC | $3.4M | 318,911 |
| MORGAN STANLEY | $3.1M | 292,508 |
Companies Similar to MED
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
NU SKIN ENTERPRISES, INC.
MGP INGREDIENTS INC
Ispire Technology Inc.
HAIN CELESTIAL GROUP INC
EDGEWELL PERSONAL CARE Co
Yatsen Holding Ltd
Limoneira CO
Waldencast plc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Consumer Staples Companies
View all Consumer Staples →Put MED on your watchlist
Track score changes the day MEDIFAST INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MED a good stock to buy?
13F Pro's AI-powered analysis of MEDIFAST INC (MED) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Staples sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MED are available on the MED stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MED is classified as a small company.
Which hedge funds own MED?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MED. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MEDIFAST INC's investment landscape.